Global Erythropoietin Drugs Market to reach USD 23.38 billion by 2027.

Global Erythropoietin Drugs Market Size study, By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application (Cancer, Hematology, Neurology and Renal Diseases) and Regional Forecasts 2021-2027
Product Code:  HALDAT_32326832
Chapter 1.Executive Summary 
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Erythropoietin Drugs Market, by Drug Class, 2019-2027 (USD Billion)
1.2.2. Erythropoietin Drugs Market, by Product, 2019-2027 (USD Billion)
1.2.3. Erythropoietin Drugs Market, by Application, 2019-2027 (USD Billion)
1.2.4. Erythropoietin Drugs Market, by, 2019-2027 (USD Billion)
1.2.5. Erythropoietin Drugs Market, by, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Erythropoietin Drugs Market Definition and Scope 
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Erythropoietin Drugs Market Dynamics 
3.1. Erythropoietin Drugs Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Increasing demand from patients of HIV and kidney Diseases
3.1.1.2. Rising incidence of diabetes and heart diseases
3.1.2. Market Challenges
3.1.2.1. High cost of production of drugs
3.1.3. Market Opportunities
3.1.3.1. Patent expiration of major drug manufacturers
Chapter 4. Global Erythropoietin Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political 
4.2.2. Economical
4.2.3. Social 
4.2.4. Technological 
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Erythropoietin Drugs Market, by Drug Class
5.1. Market Snapshot 
5.2. Global Erythropoietin Drugs Market by Drug Class, Performance - Potential Analysis
5.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)
5.4. Erythropoietin Drugs Market, Sub Segment Analysis
5.4.1. Biologics
5.4.2. Biosimilars
Chapter 6. Global Erythropoietin Drugs Market, by Product
6.1. Market Snapshot 
6.2. Global Erythropoietin Drugs Market by Product, Performance - Potential Analysis
6.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Product 2018-2027 (USD Billion)
6.4. Erythropoietin Drugs Market, Sub Segment Analysis
6.4.1. Epoetin-alfa
6.4.2. Epoetin-beta
6.4.3. Darbepoetin-alfa
6.4.4. Others
Chapter 7. Global Erythropoietin Drugs Market, by Application
7.1. Market Snapshot 
7.2. Global Erythropoietin Drugs Market by Application, Performance - Potential Analysis
7.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Application 2018-2027 (USD Billion)
7.4. Erythropoietin Drugs Market, Sub Segment Analysis
7.4.1. Cancer
7.4.2. Haematology
7.4.3. Renal Diseases
7.4.4. Neurology
Chapter 8. Global Erythropoietin Drugs Market, Regional Analysis
8.1. Erythropoietin Drugs Market, Regional Market Snapshot 
8.2. North America Erythropoietin Drugs Market 
8.2.1. U.S. Erythropoietin Drugs Market
8.2.1.1. Drug Class breakdown estimates & forecasts, 2018-2027 
8.2.1.2. Product breakdown estimates & forecasts, 2018-2027
8.2.1.3. Application breakdown estimates & forecasts, 2018-2027
8.2.2. Canada Erythropoietin Drugs Market
8.3. Europe Erythropoietin Drugs Market Snapshot
8.3.1. U.K. Erythropoietin Drugs Market 
8.3.2. Germany Erythropoietin Drugs Market
8.3.3. France Erythropoietin Drugs Market
8.3.4. Spain Erythropoietin Drugs Market
8.3.5. Italy Erythropoietin Drugs Market
8.3.6. Rest of Europe Erythropoietin Drugs Market
8.4. Asia-Pacific Erythropoietin Drugs Market Snapshot
8.4.1. China Erythropoietin Drugs Market 
8.4.2. India Erythropoietin Drugs Market 
8.4.3. Japan Erythropoietin Drugs Market
8.4.4. Australia Erythropoietin Drugs Market
8.4.5. South Korea Erythropoietin Drugs Market
8.4.6. Rest of Asia Pacific Erythropoietin Drugs Market
8.5. Latin America Erythropoietin Drugs Market Snapshot
8.5.1. Brazil Erythropoietin Drugs Market
8.5.2. Mexico Erythropoietin Drugs Market
8.6. Rest of The World Erythropoietin Drugs Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1.  Johnson & Johnson
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2.   Celltrion, Inc.
9.2.3. Teva Pharmaceutical Industries Ltd
9.2.4. Amgen, Inc.
9.2.5. Hoffman-La Roche Ltd.
9.2.6. LG Life Sciences Ltd.
9.2.7. Biocon Limited
9.2.8. Intas Pharmaceuticals Ltd.
9.2.9.  Sun Pharmaceutical Industries Ltd.
9.2.10. Dr. Reddy’s Laboratories Ltd.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption

Global Erythropoietin Drugs Market is valued approximately USD 11.05 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 11.30% over the forecast period 2021-2027. Erythropoietin is a hormone produced by the kidney that encourages the formation of red blood cells by the bone marrow. The subsequent rise in red cells increases the oxygen-carrying capacity of the blood. Erythropoietin drugs are used as a medication to treat anemia (low red blood cell count) in patients with long-term serious kidney disease (chronic kidney failure), people receiving zidovudine to treat HIV, and people receiving chemotherapy for some types of cancer. The rise in the cases of chronic kidney diseases as well as in the patients of HIV and anemia are increasing the demand for erythropoietin drugs.
According to National Kidney Foundation in 2018, kidney disease affects an estimated 37 million people in the U.S.A. In 2018, 785,883 Americans had kidney failure, and needed dialysis or a kidney transplant to survive. Also, 12 people die every day while waiting for a kidney transplant. Centre for Disease Control reports that more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have Chronic Kidney Disease (CKD). Diabetes and high blood pressure are the usual causes of CKD in adults. Other risk factors include heart disease, obesity, a family history of disease and older age. The rising diabetic and heart patients too are causing the increased demand for erythropoietin drugs. The high cost of manufacturing erythropoietin drugs, particularly in developing countries, may act as a restraint for its growth. However, as the patents of major companies are expiring in the near future, the market for generic biologics and biosimilars is ripe to capture. This acts as an opportunity for Erythropoietin Drugs Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Erythropoietin Drugs Market. Due to higher number of patients of chronic kidney diseases as well as higher per capita income and hence more expenditure on health, North America is a significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit highest growth rate for the forecast period 2021-2027 owing to the increasing cases of anemia and HIV in developing countries. Rising disposable income and government as well as private investment in healthcare sector will also boost growth in this region.

Major market player included in this report are:
Johnson & Johnson
Celltrion, Inc.
Teva Pharmaceutical Industries Ltd
Amgen, Inc.
Hoffman-La Roche Ltd.
LG Life Sciences Ltd.
Biocon Limited
Intas Pharmaceuticals Ltd.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Biologics
Biosimilars

By Product:
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

By Application:
Cancer
Hematology
Renal Diseases
Neurology

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Erythropoietin Drugs Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

Full Name*

Business Email* (Please avoid generic email IDs such as gmail, yahoo)

Phone* (Please Affix Country Code)

Need specific market information? To get a customized report, please share your exact research requirements.



Loading…